甲状腺眼症治療薬市場：治療タイプ別、投与経路別、タイプ別、診断別、エンドユーザー別、流通別-2025-2030年の世界予測

甲状腺眼症治療薬市場の2024年の市場規模は26億7,000万米ドルで、2025年にはCAGR 5.94%で28億3,000万米ドルに成長し、2030年には37億8,000万米ドルに達すると予測されています。

甲状腺眼症（Tyroid Eye Disease：TED）は、臨床的に複雑であると同時に、医療提供者がこの困難な病態を管理する方法を再構築する、進化する治療機会の両方を提示しています。近年、根底にある病態を理解し、保存的な内科的介入から外科的治療まで、多様な治療戦略を実施する上で目覚ましい進歩が見られています。本エグゼクティブサマリーでは、TED治療の多面的な状況を掘り下げ、患者ケアを再定義した科学的進歩と戦略的洞察について詳述します。このイントロダクションでは、現在の治療環境における重要な局面に焦点を当て、治療および診断手法の革新が臨床判断にどのような影響を及ぼし、患者の転帰を改善しているかを強調します。研究が深まり、新たな治療法が登場するにつれ、利害関係者は、確かな分析と戦略的な先見性を必要とする臨床実践の変容を目の当たりにしています。治療アプローチの進化は、生物学的・臨床的要因だけでなく、治療パラダイムを形成する市場力学や規制促進要因も考慮した統合的視点の必要性を強調しています。この詳細な検討は、意思決定者にとって画期的な概要となり、以降のセクションを通してより深い理解と戦略的な議論への道を開きます。

甲状腺眼症治療の展望を再定義する転換期

近年、甲状腺眼症治療の情勢は、科学的革新と市場力学の変化の両方によって、大きな変革期を迎えています。先進的な画像診断技術と診断プロトコルの強化により、臨床医がTEDを診断・分類する方法が再構築され、より早期の介入と、よりオーダーメイドの治療戦略が可能になりました。特に免疫調節薬や生物学的製剤の領域における標的治療の出現は、個別化医療への幅広いシフトを反映しています。これらの進歩は、従来の内科的治療を補完する低侵襲の外科的処置が重視されるようになってきたことと相まっています。臨床が進化するにつれて、経済的な考慮やヘルスケア政策は、治療の選択や研究開発への投資にさらに影響を及ぼします。この変革は、治療法の組み合わせを変えるだけでなく、患者管理の範囲を広げ、内分泌専門医、眼科専門医、外科専門医の学際的協力を統合しています。このエコシステムにおける包括的な変化は、技術統合、戦略的パートナーシップ、規制適応の重要な役割を浮き彫りにしています。このような状況において、この分野のリーダーたちは、満たされていないニーズに対応し、治療の有効性と質の両方を向上させるイノベーションと戦略的ビジョンを一致させることが強く求められています。このダイナミックな環境では、急速な変化に適応し、研究と臨床の新たな機会を活用するための積極的なアプローチが求められます。

セグメンテーションの重要な洞察がターゲット戦略に活かされる

市場セグメンテーションを注意深く分析すると、TED治療において的を絞った効果的な戦略を立てるために不可欠な詳細な構造が見えてくる。治療の種類を検討する際、市場は内科的介入と外科的介入を明確に区別しています。内科的治療の分野では、コルチコステロイド、免疫抑制剤、モノクローナル抗体、甲状腺ホルモン制御剤、チロシンキナーゼ阻害剤など、さまざまな治療法が詳細に分析されています。逆に、外科的治療戦略としては、眼瞼手術、眼窩減圧手術、斜視手術などがあります。治療方法と同時に、有効性と患者のコンプライアンスを決定する重要な要素である投与経路についても、静脈内、経口、局所という観点から精査されています。さらに、i型TEDとII型TEDという疾患タイプ別に市場をセグメント化することで、介入を調整する際の明確性が増します。診断手法は、血液検査、画像検査、眼窩超音波検査、放射性ヨウ素取り込み検査など、様々な検査を通して市場を追跡するもう一つの重要なセグメンテーション層を形成しています。分析対象はエンドユーザーにまで及び、病院や外来センターから専門クリニックに至るまで、それぞれがユニークな機会と課題をもたらしています。最後に、流通チャネルが重要な役割を果たし、病院薬局ネットワーク、オンライン薬局、伝統的な小売薬局などが市場を監督しています。セグメンテーションの各側面は、現在の動向を明らかにするだけでなく、将来の調査、投資決定、臨床戦略を方向付けるコンパウンドの物語に貢献しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 甲状腺疾患の世界の発生率と有病率の上昇により、効果的な治療法が必要となっています。
    • ヘルスケア従事者の間で甲状腺眼症の症状と治療法に関する認識を高める
  • 抑制要因
    • 甲状腺眼症治療薬の頻繁な製品リコールに関する懸念
  • 機会
    • 甲状腺眼症治療薬の強化に向けた製薬会社と調査機関の継続的な協力
    • 甲状腺眼症治療の革新が新たな治療法の強化につながる
  • 課題
    • 現在の甲状腺眼症治療薬に関連する潜在的な副作用および有害反応
• 市場セグメンテーション分析
  • 治療の種類：患者の視覚機能と美容上の外観を回復するための外科的治療の必要性が高まっている
  • 投与経路：効果と即効性のため、静脈内投与が好まれる傾向にある
  • タイプ：炎症を抑制し、進行を防ぐためのI型TEDの治療における甲状腺眼症治療薬の重要性
  • 診断：非侵襲性と費用対効果の高さから眼窩超音波検査の重要性が高まっている
  • エンドユーザー：便利で費用対効果の高い治療ソリューションの需要が高まる中、外来センター全体で甲状腺眼症治療薬の採用を拡大
  • 流通：専門的な治療へのシームレスなアクセスにより、病院薬局の重要性が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 甲状腺眼症治療薬市場治療の種類別

• 治療
  • コルチコステロイド
  • 免疫抑制剤
  • モノクローナル抗体
  • 甲状腺ホルモンコントロール
  • チロシンキナーゼ阻害剤
• 外科的治療
  • まぶたの手術
  • 眼窩減圧手術
  • 斜視手術

第7章 甲状腺眼症治療薬市場：投与経路別

• 静脈内
• オーラル
• トピック

第8章 甲状腺眼症治療薬市場：タイプ別

• タイプI TED
• タイプII TED

第9章 甲状腺眼症治療薬市場診断別

• 血液検査
• 画像検査
• 眼窩超音波
• 放射性ヨウ素摂取試験

第10章 甲状腺眼症治療薬市場：エンドユーザー別

• 病院
• 外来センター
• 専門クリニック

第11章 甲状腺眼症治療薬市場配布別

• 病院薬局
• オンライン薬局
• 小売薬局

第12章 南北アメリカの甲状腺眼症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の甲状腺眼症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの甲状腺眼症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• ACELYRIN, INC.
• Amgen Inc.
• argenx SE
• Bausch & Lomb Incorporated
• Biocon Limited
• BioXpress Therapeutics SA
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genmab A/S
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Hetero Drugs Limited
• Immunovant, Inc.
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson Services Inc.
• Lupin Limited
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sling Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.
• Viridian Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. THYROID EYE DISEASE TREATMENTS MARKET MULTI-CURRENCY
• FIGURE 2. THYROID EYE DISEASE TREATMENTS MARKET MULTI-LANGUAGE
• FIGURE 3. THYROID EYE DISEASE TREATMENTS MARKET RESEARCH PROCESS
• FIGURE 4. THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THYROID EYE DISEASE TREATMENTS MARKET DYNAMICS
• TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 71. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 107. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 113. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 115. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 121. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 252. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 253. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 254. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 255. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 258. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 259. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 284. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 285. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 286. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 287. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 288. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 289. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 290. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 291. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 292. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 293. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 294. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 295. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 296. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 297. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 298. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 299. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS

The Thyroid Eye Disease Treatments Market was valued at USD 2.67 billion in 2024 and is projected to grow to USD 2.83 billion in 2025, with a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

Thyroid eye disease (TED) presents both clinical complexities and evolving therapeutic opportunities that are reshaping the manner in which healthcare providers manage this challenging condition. Over recent years, remarkable progress has been made in understanding the underlying pathology and implementing diverse treatment strategies, from conservative medical interventions to surgical remedies. This executive summary delves into the multifaceted landscape of TED treatments, detailing the scientific advances and strategic insights that have redefined patient care. In this introductory section, the focus is on framing the critical aspects of the current treatment environment, highlighting how innovations in therapy and diagnostic methodologies are influencing clinical decisions and improving patient outcomes. As research deepens and new treatment modalities emerge, stakeholders are witnessing a transformation in clinical practice that demands robust analysis and strategic foresight. The evolution in therapeutic approaches underscores the necessity of an integrative perspective-one that not only considers the biological and clinical factors but also the market dynamics and regulatory drivers that shape treatment paradigms. This detailed exploration serves as a ground-breaking overview for decision-makers, paving the way for a deeper understanding and strategic discussion throughout the subsequent sections.

Transformative Shifts Redefining the Thyroid Eye Disease Treatment Landscape

In recent years, the landscape of thyroid eye disease treatment has undergone significant transformative shifts, driven by both scientific innovations and changing market dynamics. Advanced imaging technologies and enhanced diagnostic protocols have reshaped how clinicians diagnose and classify TED, enabling earlier intervention and more tailored treatment strategies. The emergence of targeted therapies, particularly in the realm of immunomodulatory and biologic treatments, reflects a broader shift toward personalized medicine. These advances are coupled with a growing emphasis on minimally invasive surgical procedures that complement traditional medical treatments. As clinical practices evolve, economic considerations and healthcare policies further influence treatment selections and investment in research and development. This transformation is not only altering the therapeutic mix but also broadening the scope of patient management, integrating multi-disciplinary collaborations between endocrinologists, ophthalmologists, and surgical experts. The comprehensive changes within this ecosystem highlight the critical role of technological integration, strategic partnerships, and regulatory adaptations. In this context, leaders in the field are urged to align their strategic vision with innovations that address unmet needs and improve both the efficacy and quality of care. This dynamic environment demands a proactive approach to adapt to rapid changes and to harness emerging opportunities in research and clinical practice.

Key Segmentation Insights Informing Targeted Strategies

A careful dissection of market segmentation reveals a detailed structure that is crucial for crafting targeted and effective strategies for TED treatments. When considering treatment types, the market distinctly differentiates between medical and surgical interventions. The medical treatment arm is meticulously analyzed through a spectrum of therapies that include corticosteroids, immunosuppressants, monoclonal antibodies, agents for thyroid hormone control, and tyrosine kinase inhibitors. Conversely, surgical treatment strategies are further explored through procedures such as eyelid surgery, orbital decompression surgery, and strabismus surgery. In tandem with treatment modality, the route of administration-a key determinant of both efficacy and patient compliance-has been scrutinized in terms of intravenous, oral, and topical applications. Additionally, segmenting the market by disease type, namely between Type I TED and Type II TED, offers further clarity in tailoring interventions. Diagnostic methodologies form another important segmentation layer that tracks the market through various tests including blood tests, imaging tests, orbital ultrasound, and radioactive iodine uptake tests. Analysis extends to the end-user dimension, where care settings span from hospitals and outpatient centers to specialty clinics, each presenting unique opportunities and challenges. Finally, distribution channels play a critical role, with market oversight including hospital pharmacy networks, online pharmacies, and traditional retail pharmacies. Each segmentation facet contributes to a compounding narrative that not only illuminates current trends but also directs future research, investment decisions, and clinical strategies.

Based on Treatment Type, market is studied across Medical Treatment and Surgical Treatment. The Medical Treatment is further studied across Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Thyroid Hormone Control, and Tyrosine Kinase Inhibitors. The Surgical Treatment is further studied across Eyelid Surgery, Orbital Decompression Surgery, and Strabismus Surgery.

Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.

Based on Type, market is studied across Type I TED and Type II TED.

Based on Diagnosis, market is studied across Blood Test, Imaging Test, Orbital Ultrasound, and Radioactive Iodine Uptake Test.

Based on End-User, market is studied across Hospitals, Outpatient Centers, and Specialty Clinics.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Key Regional Insights Shaping Global Market Dynamics

The TED treatment market is characterized by distinct regional variations, reflecting both local healthcare infrastructure and regional economic dynamics. In the Americas, robust healthcare spending, coupled with strong research and development initiatives, creates a fertile ground for innovation and rapid adoption of advanced therapeutic modalities. Meanwhile, Europe, Middle East & Africa experience a blend of mature healthcare markets and emerging opportunities, driven by a careful balance between tradition and innovation. European nations, in particular, continually enhance diagnostic technologies and treatment protocols, while markets in the Middle East and Africa adapt rapidly to dynamic demand patterns through strategic partnerships and policy reforms. The Asia-Pacific region stands out with its fast-growing healthcare infrastructure and increasing investment in research, making it a pivotal arena for both new market entrants and established players. These regional insights underscore the critical need for tailored strategies that address local demands while leveraging global best practices. Interregional differences in regulatory frameworks, reimbursement policies, and patient preferences remain at the core of strategic decision-making processes that drive market growth and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Competitive Landscape and Innovation

The competitive arena of thyroid eye disease treatment is populated by a diverse group of key companies that drive innovation, invest in advanced research, and expand their market presence. Market leaders including Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, and Bausch & Lomb Incorporated are at the forefront of developing novel therapeutic interventions and enhancing patient care. In addition, companies such as Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, and Dr. Reddy's Laboratories Ltd. continue to push the boundaries of both medical and surgical treatment options. Prominent names such as Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, and H. Lundbeck A/S reaffirm the commitment to robust innovation pipelines and targeted clinical solutions. Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., and Johnson & Johnson Services Inc. bring to the table significant advancements and an acute understanding of market needs. The competitive landscape is further enriched by Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc., each contributing distinct approaches that range from breakthrough therapies to enhanced surgical techniques. This confluence of expertise reinforces the industry's multifaceted approach in addressing the clinical complexities of thyroid eye disease and sets the stage for future growth and competitive differentiation.

The report delves into recent significant developments in the Thyroid Eye Disease Treatments Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, Bausch & Lomb Incorporated, Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, H. Lundbeck A/S, Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc.. Actionable Recommendations for Navigating the Transformative Market

Industry leaders are encouraged to adopt a proactive and strategic approach in order to capitalize on the rapidly transforming landscape of thyroid eye disease treatments. Stakeholders should prioritize investment in innovative therapeutic research, particularly in the sphere of targeted biologics and minimally invasive surgical techniques. Given the nuanced segmentation across treatment types, routes of administration, disease types, and diagnostic protocols, it is essential to develop tailored strategies that address individual patient profiles and local market dynamics. Emphasis should be placed on integrating advanced diagnostic tools and data analytics into routine clinical practice, which not only improves precision but also facilitates early intervention. Furthermore, forging robust strategic alliances, both on a regional and cross-regional level, can help in pooling expertise and expediting the adoption of best practices. There is a clear imperative for optimizing distribution networks to ensure timely accessibility of therapies, alongside streamlining processes within hospital and online pharmacy channels. Overall, a deepened focus on understanding market segmentation, regional disparities, and the competitive landscape will provide industry leaders with the insights needed to mitigate risk and harness the substantial opportunities inherent in this evolving therapeutic domain.

Conclusion: Embracing a Future of Innovation and Personalized Care

In conclusion, the landscape of thyroid eye disease treatments is characterized by a dynamic interplay between innovation, strategic market segmentation, and evolving regional dynamics. As stakeholders navigate the complex therapeutic ecosystem, it is imperative to consider the diversity of treatment modalities, ranging from cutting-edge medical interventions to refined surgical techniques. The in-depth segmentation analysis - encompassing treatment type, route of administration, disease classification, diagnostic methodology, end-user setting, and distribution channels - has revealed not only the intricacies of current practices but also the directions for future innovation and strategic planning. Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa provide robust infrastructure and progressive policy environments, the Asia-Pacific market offers immense potential with its rapid expansion and increasing research investments. Coupled with the competitive drive of leading companies, the market is poised for transformative growth that prioritizes personalized care and data-driven decision making. This comprehensive review underscores the necessity for adaptability and strategic foresight among clinicians, manufacturers, and policy makers, all of whom play pivotal roles in shaping the future of TED treatment paradigms.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising global incidence and prevalence of thyroid disorders necessitates effective treatment options
    • 5.1.1.2. Increasing awareness about symptoms and treatments for thyroid eye disease among healthcare providers
  • 5.1.2. Restraints
    • 5.1.2.1. Concern associated with frequent product recalls of thyroid eye disease treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing collaborations between pharmaceutical companies and research institutions enhancing thyroid eye disease treatment product
    • 5.1.3.2. Rising advancements in innovation of thyroid eye disease treatment to enhance novel therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects and adverse reactions associated with current thyroid eye disease treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing need for surgical treatments to restore visual function and cosmetic appearance among patients
  • 5.2.2. Route of Administration: Rising preference for intravenous administration owing to efficacy and immediate relief
  • 5.2.3. Type: Significant importance of thyroid eye disease treatments for treating type I TED for controlling inflammation and preventing progression
  • 5.2.4. Diagnosis: Increasing significance for orbital ultrasound owing to its non-invasive appeal and cost-effectiveness
  • 5.2.5. End-User: Expanding adoption of thyroid eye disease treatments across outpatient centers with rising need for convenient and cost-effective treatment solutions
  • 5.2.6. Distribution: Growing importance of hospital pharmacies owing to seamless access to specialized treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thyroid Eye Disease Treatments Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medical Treatment
  • 6.2.1. Corticosteroids
  • 6.2.2. Immunosuppressants
  • 6.2.3. Monoclonal Antibodies
  • 6.2.4. Thyroid Hormone Control
  • 6.2.5. Tyrosine Kinase Inhibitors
• 6.3. Surgical Treatment
  • 6.3.1. Eyelid Surgery
  • 6.3.2. Orbital Decompression Surgery
  • 6.3.3. Strabismus Surgery

7. Thyroid Eye Disease Treatments Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral
• 7.4. Topical

8. Thyroid Eye Disease Treatments Market, by Type

• 8.1. Introduction
• 8.2. Type I TED
• 8.3. Type II TED

9. Thyroid Eye Disease Treatments Market, by Diagnosis

• 9.1. Introduction
• 9.2. Blood Test
• 9.3. Imaging Test
• 9.4. Orbital Ultrasound
• 9.5. Radioactive Iodine Uptake Test

10. Thyroid Eye Disease Treatments Market, by End-User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Outpatient Centers
• 10.4. Specialty Clinics

11. Thyroid Eye Disease Treatments Market, by Distribution

• 11.1. Introduction
• 11.2. Hospital Pharmacy
• 11.3. Online Pharmacy
• 11.4. Retail Pharmacy

12. Americas Thyroid Eye Disease Treatments Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Thyroid Eye Disease Treatments Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Sling Therapeutics reveals advance phase 2b/3 trial results for linsitinib in thyroid eye disease management
  • 15.3.2. Acelyrin, Inc. announces new Phase 2 data and Phase 3 plans for lonigutamab in treating thyroid eye disease
  • 15.3.3. Lundbeck launches advance clinical trial of CD40L blocker Lu AG22515 targeting thyroid eye disease
  • 15.3.4. Amgen announced TEPEZZA approval in Japan marks a significant advancement in thyroid eye disease treatment
  • 15.3.5. Viridian Therapeutics enhances with Phase III trials of VRDN-003 for treating thyroid eye disease
  • 15.3.6. Verana Health announces launch of Qdata thyroid eye disease
  • 15.3.7. Xeris Biopharma finalizes worldwide licensing agreement for Xeriject teprotumumab in thyroid eye disease treatment
  • 15.3.8. Viridian Therapeutics partners with Ypsomed AG to enhance subcutaneous thyroid eye disease treatment
  • 15.3.9. Amgen completes acquisition of Horizon Therapeutics to expand rare disease treatment portfolio
  • 15.3.10. Tourmaline Bio announces FDA clearance of Investigational New Drug application for TOUR006
• 15.4. Strategy Analysis & Recommendation
  • 15.4.1. Sling Therapeutics, Inc.
  • 15.4.2. Amgen Inc.
  • 15.4.3. Viridian Therapeutics, Inc. by miRagen Therapeutics, Inc.
  • 15.4.4. ACELYRIN, INC.

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. ACELYRIN, INC.
• 4. Amgen Inc.
• 5. argenx SE
• 6. Bausch & Lomb Incorporated
• 7. Biocon Limited
• 8. BioXpress Therapeutics SA
• 9. Cipla Limited
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche AG
• 13. Genmab A/S
• 14. GlaxoSmithKline PLC
• 15. H. Lundbeck A/S
• 16. Hetero Drugs Limited
• 17. Immunovant, Inc.
• 18. Intas Pharmaceuticals Ltd.
• 19. Johnson & Johnson Services Inc.
• 20. Lupin Limited
• 21. Merck KGaA
• 22. Novartis AG
• 23. Pfizer, Inc.
• 24. Regeneron Pharmaceuticals, Inc.
• 25. Sling Therapeutics, Inc.
• 26. Teva Pharmaceutical Industries Ltd.
• 27. Viridian Therapeutics, Inc.